GlassScriptPhysician profile
Lindsay Beth Fehring
NPI 1184347700
$5,321.61
in general payments reported to CMS, 2019-2025
30 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $590 · 2024: $2,916 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856 · Consulting Fee: $305 · Education: $33.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.66 |
| Consulting Fee | $305.00 |
| Education | $33.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $791.37 | 2023-2025 | Tremfya, Stelara, Simponi |
| Janssen Scientific Affairs, LLC | $503.46 | 2023-2024 | Tremfya, Stelara |
| Abbvie INC. | $446.67 | 2023-2025 | |
| Gilead Sciences, INC. | $406.28 | 2024 | Livdelzi, Veklury |
| Phathom Pharmaceuticals, INC. | $310.72 | 2024-2025 | Voquezna |
| Becton, Dickinson and Company | $305.00 | 2025 | |
| Genzyme Corporation | $277.09 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.43 | 2024-2025 | Xifaxan, Trulance |
| Mallinckrodt Hospital Products INC. | $267.70 | 2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $265.47 | 2024-2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $253.26 | 2024 | |
| Pfizer INC. | $232.13 | 2024-2025 | |
| Lilly USA, LLC | $220.55 | 2024-2025 | Omvoh, Zepbound |
| Astrazeneca Pharmaceuticals LP | $127.94 | 2022 | |
| Shionogi INC | $124.99 | 2024 | Fetroja |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $116.51 | 2024 | |
| Madrigal Pharmaceuticals | $62.39 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $57.36 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $51.10 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $45.58 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $33.37 | 2024 | Injectafer |
| Celgene Corporation | $28.19 | 2023-2024 | Zeposia |
| Medtronic, INC. | $18.00 | 2023 | |
| Novo Nordisk INC | $17.24 | 2025 | Wegovy |
| Orphalan INC | $16.21 | 2025 | Cuvrior |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2024 | Cyltezo |
| Celltrion USA INC. | $15.01 | 2024 | Zymfentra |
| Aimmune Therapeutics, INC. | $14.57 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $14.36 | 2025 | Iqirvo |
| Teleflex LLC | $13.20 | 2024 | Solesta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Fehring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.